Скачайте изображение (превью) выбрав качество

320x180 480x360 640x480 1280x720

Watch on Radcliffe Cardiology:

In this late-breaking interview focusing on the PACMAN-AMI Trial, Prof Lorenz Räber (Bern University Hospital, University of Bern, Bern, CH) reveals that the use of alirocumab reduced coronary plaque regression in patients with acute myocardial infarction (AMI). Originally presented by Prof Raber at ACC 2022, these findings suggest that alirocumab, on top of high-intensity statin therapy, may be an effective treatment for AMI when compared to placebo (NCT03067844).

Discussion Points:
1. Importance of this Trial
2. Study Design and Patient Cohort
3. Outcomes of this Study
4. Take-home Messages for Clinicians
5. Further Study Needed

Recorded on-site in Washington DC, ACC Conference 2022.
Interviewer: Mirjam Boros
Editor: Jordan Rance

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Чтобы скачать видео "ACC 22: PACMAN-AMI Shows Reduced Plaque Regression in AMI Patients Treated with Alirocumab" передвинте ползунок вправо